SPACs are resurging as a virtually hassle-free alternative to IPOs, but are just now becoming a factor for biotech, reports BioSpace. Biotech is a burgeoning business, and non-traditional investors with little biotech knowledge or expertise gravitate to biotech SPACS. They have money to invest and want to get in on the ground floor of what they hope will become the next Amgen or Genentech. Read more.
Related Posts
Sam Altman-Backed Fission Tech Company Oklo Merging with His AltC Acquisition in $850M Deal
AltC was co-founded by Sam Altman and Churchill Capital in July 2021. Altman serves as CEO of AltC and has been chairman of Oklo since 2015.
Deep Medicine Acquisition and TruGolf Merging in $125M Deal
The SPAC raised $110 million in an October 2021 IPO with initial plans to focus on targets in the healthcare industry with an enterprise value of approximately $500 million to $1 billion.
Eco Modular to Go Public Through Merger with Zalatoris II in $600M Deal
The transaction is expected to provide a minimum of $66 million in net proceeds after transaction expenses.
Super Apps Merging with Technology & Telecommunication Acquisition in $1.1B Deal
A payment of $235 million will be made at closing with the remaining $865 million subject to earn-out provisions.